Yan, L.; Yi, J.; Liu, D.; Li, J.; Baidoo, A.A.H.; Xie, L.
Baseline Anti-SARS-CoV-2 IgG and Protection from Symptomatic Infection: Post Hoc Analysis of the SCTV01E Phase 3 Randomized Trial. Vaccines 2025, 13, 984.
https://doi.org/10.3390/vaccines13090984
AMA Style
Yan L, Yi J, Liu D, Li J, Baidoo AAH, Xie L.
Baseline Anti-SARS-CoV-2 IgG and Protection from Symptomatic Infection: Post Hoc Analysis of the SCTV01E Phase 3 Randomized Trial. Vaccines. 2025; 13(9):984.
https://doi.org/10.3390/vaccines13090984
Chicago/Turabian Style
Yan, Lixin, Jiang Yi, Dongfang Liu, Jian Li, Adam Abdul Hakeem Baidoo, and Liangzhi Xie.
2025. "Baseline Anti-SARS-CoV-2 IgG and Protection from Symptomatic Infection: Post Hoc Analysis of the SCTV01E Phase 3 Randomized Trial" Vaccines 13, no. 9: 984.
https://doi.org/10.3390/vaccines13090984
APA Style
Yan, L., Yi, J., Liu, D., Li, J., Baidoo, A. A. H., & Xie, L.
(2025). Baseline Anti-SARS-CoV-2 IgG and Protection from Symptomatic Infection: Post Hoc Analysis of the SCTV01E Phase 3 Randomized Trial. Vaccines, 13(9), 984.
https://doi.org/10.3390/vaccines13090984